Thermo Fisher Scientific Inc. (TMO) Fair Value 2026

TMO · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

7.8 /10

32 fundamental signals · 10 models active

Value Trap Risk

SAFE (13/100)

Quick Summary — As of 2026-08-27, Thermo Fisher Scientific Inc. (TMO) trades at $630.70, versus a $282.13 median fair value across its 10 active models — 55.3% below the current price. QOC: 7.8/10. Value Trap Risk: 13/100 (SAFE). 10/13 models active. Within that set, the Bayesian DCF component alone returns $290.37.

Key Facts

Ticker
TMO
Price
$630.70
Quality Score
7.8/10
Value Trap Risk
13/100
Models Active
10/13
Last Updated
Strength: 10 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is Thermo Fisher Scientific Inc. (TMO) Undervalued or Overvalued in 2026?

According to CirclFi’s 10-model valuation engine, Thermo Fisher Scientific Inc. (TMO) appears overvalued as of : the median of 10 independent fair value estimates is $282.13, 55.3% below the current price of $630.70. Estimates range from $134.87 to $959.50. TMO scores 7.8/10 on fundamental quality and 13/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. TMO’s -55.3% gap is wider than that market norm, and the Diagnostics & Research sector median is -54.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Thermo Fisher Scientific Inc. Stock in 2026? →

What Fair Value Does Each Model Give TMO?

10 Intrinsic Value Models vs. Current Price ($630.70)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $290.37 -54.0%
Intrinsic · High Conviction
 $149.64 -76.3%
Ensemble · Low Conviction
 $273.89 -56.6%
Intrinsic · High Conviction
 $134.87 -78.6%
Unlock the Full Matrix

Access 6 additional models including Markov DDM, ML-RIV, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 10 Models →

Cancel anytime · No contracts · Instant access

What Is TMO's Fair Value Range?

Spread across 10 independent models · $134.87 to $959.50

CirclFi's 10 active models place Thermo Fisher Scientific Inc. (TMO) between $134.87 and $959.50 per share, a spread of 292% of the median. The median of that range — $282.13 — is the fair value CirclFi publishes for TMO, against a current price of $630.70.

Low · EROICHigh · Regime Cross
$134.87median $282.13$959.50
Where the range comes from
Most bearish modelEROIC Spread$134.87
Most bullish modelRegime Cross-Sectional$959.50
Model agreement1 bullish · 9 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for TMO. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on TMO, not a CirclFi price target. How each model works →

What Is Thermo Fisher Scientific Inc. (TMO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Thermo Fisher Scientific Inc.'s intrinsic value is estimated at $282.13. Trading at its current price of $630.70, the valuation engine raises significant caution: 9 of 10 models flag downside risk, projecting a median implied return of -55.3%. The most optimistic model, Regime Cross, places fair value at $959.50 (+52.1%), while EROIC — the most conservative — estimates $134.87 (-78.6%). This +130.7% gap reflects genuine analytical uncertainty about Thermo Fisher Scientific Inc.'s intrinsic worth. Among models with highest confidence, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About TMO?

10 of 13 models are currently active for TMO. Of these, 1 model suggests upside while 9 models suggest overvaluation. Taken together, their median fair value for TMO is $282.13 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $290.37 on its own, implying -54.0% downside from the current price. See which stocks rank higher →

How Does TMO Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, TMO ranks #12 by Quality of Company score. CirclFi's QOC score of 7.8/10 evaluates 32 fundamental signals. A score of 7.8 indicates above-average quality.

Thermo Fisher Scientific Inc.'s positioning within the Diagnostics & Research segment means that biosimilar competition timeline plays an outsized role in fundamental analysis. The sector's unique characteristics — including orphan drug designation — shape both the opportunity set and risk profile.

Is TMO a Value Trap?

CirclFi's Value Trap algorithm assigns TMO a score of 13/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

10 of 13 models are active for Thermo Fisher Scientific Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Thermo Fisher Scientific Inc. scores 7.8 out of 10 on our 32-signal quality assessment, a strong rating that demonstrates strong fundamentals across the majority of our quality signals. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +130.7% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every TMO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across TMO's 10 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Thermo Fisher Scientific Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

DGXQuest Diagnostics IncorporatedQOC 7.9BLLNBillionToOne, Inc.QOC 7.7SHCSotera Health CompanyQOC 8.1WATWaters CorporationQOC 7.7DHRDanaher CorporationQOC 8.1LHLabcorp Holdings Inc.QOC 7.7CRLCharles River Laboratories International, Inc.QOC 6.9QUCYQuantum Cyber N.V.QOC 5.6MBAIMBody AI Corp.QOC 2.5IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: DGX · BLLN · SHC · WAT · DHR · LH · CRL · QUCY · MBAI · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to TMO?

7 companies across all industries closest to TMO’s Quality of Company score of 7.8/10.

EXRExtra Space Storage Inc.QOC 7.8AFLAflac IncorporatedQOC 7.8ATRCAtriCure, Inc.QOC 7.8PEBKPeoples Bancorp of North Carolina, Inc.QOC 7.8PDFSPDF Solutions, Inc.QOC 7.8NOGNorthern Oil and Gas, Inc.QOC 7.8NVDANVIDIA CorporationQOC 10.0

Read investment analysis: EXR · AFL · ATRC · PEBK · PDFS · NOG · NVDA

What Else Do Investors Ask About Thermo Fisher Scientific Inc.’s Valuation?

What is Thermo Fisher Scientific Inc.'s intrinsic value in 2026?

CirclFi puts Thermo Fisher Scientific Inc. (TMO)'s intrinsic value at $282.13 — the median of 10 independent model estimates as of 2026-08-27, ranging from $134.87 to $959.50. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $290.37 on its own. The Quality of Company score is 7.8/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is TMO overvalued or undervalued right now?

At $630.70, 1 of 10 active models suggest TMO may be undervalued, while 9 indicate potential overvaluation. The median of all 10 fair value estimates is $282.13, 55.3% below the current price of $630.70 — a consensus view that TMO is overvalued. The assessment depends on which methodology best fits Thermo Fisher Scientific Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 7.8 mean for TMO?

Thermo Fisher Scientific Inc.'s QOC of 7.8/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on TMO?

CirclFi analyzes TMO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 10 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on TMO?

Of the 10 models currently active on TMO, Regime Cross-Sectional is the most bullish at $959.50 per share, and EROIC Spread is the most bearish at $134.87. CirclFi's published fair value for TMO is the median of that range, $282.13, not either extreme. The gap between the two ends equals 292% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is TMO a value trap in 2026?

Thermo Fisher Scientific Inc.'s Value Trap score is 13/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 10-model valuation engine, Thermo Fisher Scientific Inc. (TMO) has a median fair value of $282.13 — 55.3% below the current price of $630.70 — as of 2026-08-27.” Source: circlfi.com/stock/TMO/ · Methodology
Primary sources for this TMO valuation
  • Financial statements: Thermo Fisher Scientific Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0000097745) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for TMO as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 10 mathematical frameworks give you clarity on TMO.

Unlock All 10 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

6 models hidden for TMO Unlock All 10 — $39/mo